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and the graft survival rate data was obtained from the
clinical studies of both drugs in Japan. 
RESULTS: Expected cost-effectiveness ratios per graft
surviving at 90 days were $13,730 ($1  120 Yen) for
mycophenolate mofetil, and $29,060 for muromonab
CD3 for the baseline analysis. Thus, a $12,400 cost-savings
of mycophenolate mofetil was observed. Comprehensive
sensitive analyses were done, such as drug efficacy rate in
the initial treatment, rejection rate after the initial treat-
ment, and graft loss rate. However, the cost-saving by my-
cophenolate mofetil continued to be found for all of these
cases so that the model can be considered to be robust. 
CONCLUSIONS: Mycophenolate mofetil treatment
proved to be cost-effective in comparison with muromonab
CD3 for intractable acute rejection in renal transplantation.
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OBJECTIVE: The purpose of this study was to analyze
the cost-utility ratios of liver and kidney transplantations
in a German transplant centre. 
METHOD: Sixty patients with liver transplantation and
77 patients with kidney transplantation were included in
a full cost assessment based on process costs with differ-
ent cost drivers (e.g., patient days, dialysis treatments,
admission) and based on the friction cost method to cal-
culate indirect costs. Benefits of transplantation were as-
sessed employing the EuroQol quality of life instrument
(German version). Both costs and benefits were dis-
counted with a discount rate of 5%. Several sensitivity
analyses were performed. 
RESULTS: Discounted with 5% and with a time horizon
of 20 years dialysis patients could gain 0.76 quality-
adjusted life-years (QALYs). Liver transplant recipients
gained 3.85 QALYs. The cost per QALYs gained ratio is
76,800 DM for liver transplantation. Gross cost per
QALY of dialysis patients is 147,800 DM (kidney trans-
plantation: 38,300 DM). Liver patients have a higher po-
tential to experience a significant gain in quality of life
than dialysis patients. On the other hand the long-term
results of patients who received a kidney transplantation
are better in terms of mortality compared to patients who
received a liver transplantation. Nevertheless, patients
with liver transplantation experience higher numbers of
QALYs gained than patients with kidney transplantation,
as the mortality of dialysis patients does not change after
transplantation (except for the operation risk). 
CONCLUSION: Liver transplantation is still a high-cost
procedure with a high cost-utility ratio compared to
other medical interventions. To avoid problems of fi-
nancing the cost of liver transplantation have to be de-
creased and/or outcomes (mortality, quality of life) must
be improved.
ECONOMIC AND OUTCOMES ISSUES OF 
PAIN MANAGEMENT
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Pain management guidelines advise opioids for the man-
agement of chronic moderate to severe pain, both malig-
nant and non-malignant. Among the options for opioid
therapy, oral opioids and transdermal fentanyl offer pa-
tient convenience and cost advantages over parenteral
(e.g., IV or IT) administration. After efficacy, patient con-
venience and cost are primary criteria in selecting chronic
pain control therapy. In order to better understand the
distinctions in these criteria, an economic framework for
evaluating transdermal fentanyl and oral opioids is
needed. 
OBJECTIVE: To develop an economic framework for
evaluating transdermal fentanyl and oral opioids for
management of chronic moderate to severe malignant
and non-malignant pain. 
METHODS: Based on a systematic review of the litera-
ture, a decision analytic model was developed. It is com-
prised of three phases: titration (lasting up to several
days), stabilization (30 days), and long-term use (through
the first year). The primary outcomes are costs, quality-
adjusted life-days (QALDs), and incremental cost-utility
ratios. Probabilities of events and disutility values were
determined from clinical trials of transdermal fentanyl,
controlled release morphine, and controlled release oxy-
codone, supplemented when necessary with expert opin-
ion. Costs were derived from publicly available data. 
RESULTS: The key cost drivers are opioid price, the
probability of switching to an alternative therapy, and
the cost of treating nausea and vomiting. The primary
parameters influencing QALDs are the probability of sus-
tained pain control and the probability and disutility of
chronic constipation. 
CONCLUSION: This model may be used to guide data
collection in head-to-head clinical trials, and may be used
by individual decision-makers to inform selection of the
optimal opioid for chronic pain management.
PCP2
IMPACT OF PATIENT EDUCATION ON 
QUALITY OF LIFE IN HEADACHE TREATMENT
Solomon GD1, Mannix LK2
1Cleveland Clinic Foundation, Cleveland, OH, USA; 2Adelman 
Headache Center, Greensboro, NC, USA
OBJECTIVE: This study compares the impact of patient
education with individualized headache management on
health-related quality of life. 
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METHODS: We compared baseline and 1-month post-
intervention scores from the SF-36 from two previously
reported study groups: headache patients at a headache
clinic (individualized therapy group) and headache suf-
ferers attending headache seminars at their workplaces
(education group). Research using the SF-36 determined
that the domains of role—physical, bodily pain, role—
emotional, and social functioning are most impacted by
chronic headache. For ethical reasons, the individualized
treatment group was not treated with education alone,
therefore their scores are shown for comparison only. No
statistical analysis was performed.
RESULTS: In this study 461 consecutive new patients
seeking headache care at the Cleveland Clinic Headache
Center were compared with 368 headache sufferers at-
tending headache seminars at their workplaces. Both
groups had similar ages, gender mix, and duration of
headache. The individualized therapy group had signifi-
cantly lower SF-36 scores at baseline.
CONCLUSIONS: The patient education component of
headache treatment has a measurable and clinically sig-
nificant impact on health-related quality of life as mea-
sured by the SF-36. Patient education appears to have as
significant a role as comprehensive treatment in the key
headache domain of role–emotional. In other mental
health domains, education alone appears to have a major
influence on improvement. In physical domains such as
bodily pain and role–physical, the impact of pharmaco-
logic therapy appears to have a greater impact.
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Awareness of acetaminophen-related liver toxicity has
been growing. However, its frequency and cost have not
been well documented on a population basis. 
OBJECTIVE: To estimate the incidence and costs of
hepatotoxicity related to acetaminophen use for the Cali-
fornia Medicaid program (Medi-Cal). 
METHODS: This study was based on administrative
claims data for a 10% random sample of Medi-Cal recip-
ients in 1996. Individuals with one or more inpatient or
outpatient claims in 1996 with ICD-9-CM diagnoses of
acetaminophen-related liver toxicity were selected for in-
clusion in this analysis. An episode of treatment was de-
fined as the period of time between the dates of hospital
admission and discharge for which at least one qualifying
diagnosis was listed, or as a day of outpatient treatment
on which a patient had a qualifying diagnosis. All ser-
vices occurring during an episode were assumed to be re-
lated to acetaminophen liver toxicity.
RESULTS: A total of 244 recipients in our 10% sample
had one or more treatment episodes of acetaminophen-
related liver toxicity during 1996 (approximately 41 per-
sons per 100,000 eligibles), and over half of these oc-
curred in persons under 21 years of age. Approximately
20% of patients required admission to a hospital for
treatment. The average cost per patient with liver toxicity
was estimated to be approximately $1070. 
CONCLUSIONS: Based on our estimates of incidence
and per-person expenditures, annual spending by the
Medi-Cal program for acetaminophen-related hepatotox-
icity is projected to be approximately $2.6 million in
1996. The actual incidence of this problem is likely to be
greater than that reported here, since this study only in-
cludes poisonings that led to a medical encounter rather
than all possible occurrences.
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Measuring quality of life (QoL) has become a vital part
of assessing effects of migraine treatment in many inter-
national studies. However, only recently have measures
assessing patients’ perceptions of and satisfaction with
migraine treatment been available and none with linguis-
tically validated translations. Prior to use in an interna-
tional trial, the PPMQ (developed in US English) under-
went linguistic validation in 16 languages. 
METHODS: A QOL specialist coordinated the transla-
tion process of the PPMQ in each target country using
the following methodology: 1) two forward translations
by professional, native speaking translators of the target
language who were fluent in English; 2) comparison and
reconciliation of the translations by a QOL specialist and
translators; 3) backward translation by a native English
speaker; 4) comparison of the source and backward ver-
sion; 5) review of the translation by a clinician in each
country; 6) international harmonization. 
RESULTS: Linguistic, conceptual, and cultural issues
emerged when translating idiomatic phrases and response
scales. “How consistently the medication prevented pain
from coming back” had to be expressed through “reli-
ably” or “constantly.” Cultures less used to completing
questionnaires had difficulty understanding instructions
inviting respondents to express satisfaction with medica-
Change from baseline SF-36 score
Domain Education Individualized therapy
Physical functioning 0.3 2.5
Role–Physical 6.1 11.4
Bodily pain 3.9 9.1
General health 1.8 1.8
Vitality 4.4 2.8
Social functioning 5.5 9.2
Role–Emotional 7.5 7.5
Mental health 1.9 3.2
